

What sets EcoR1 apart?

BLEEDING EDGE SCIENCE IS OUR COMFORT ZONE

EcoR1 Capital LLC is a fundamental biotechnology-focused investment advisory firm. Based in San Francisco, EcoR1 evaluates and selects extraordinary biotechnology companies that are pursuing the highest quality science and demonstrate strong business fundamentals.

Like the EcoR1 restriction enzyme which helped to transform the biomedical field, EcoR1 seeks to help move medical research forward through investments into compelling biotech companies that are developing promising new solutions for untreated diseases.

[Contact the EcoR1 team >](#)

PARTNERSHIP:

We nurture lasting relationships.

POTENTIAL:

We expand the possibilities of science.




PROGRESS:

We are committed to innovation.

EcoR1 is committed to helping passionate drug hunters change the world.

Forging a new path

Advancements in biotech are happening at a breakneck pace, and EcoR1 has the drive and vision to help patients with the most innovative science.



Investing in Progress

EcoR1 seeks to move medical research forward through thoughtful investments that are evaluated for scientific merit and business case.

A Passion for Patients

Advancements in the biotech industry affect the lives of many. EcoR1 is committed to playing a role in finding answers for unmet medical needs.

Looking for the Exceptional

EcoR1 identifies gutsy companies that have committed management and the potential to create value over and over again.

We believe people are the most important factors in any investment opportunity.

// LEADERSHIP

Committed to success

The EcoR1 team shepherds great drugs and great people over the peaks and valleys of drug discovery and development. Learn more about our leadership team.

OLEG NODELMAN

FOUNDER AND MANAGING DIRECTOR

SARAH MARRIOTT

COO AND CCO

CATHERINE MCWILLIAMS

DIRECTOR OF PARTNER RELATIONS

SCOTT PERLEN

CFO

SCOTT PLATSHON

PRINCIPAL

DEVEN SANON

ANALYST

CAROLINE STOUT

PRINCIPAL

BASHEER ZADA


ANALYST

SARAH SPENCER

ANALYST

**EcoR1 helps move medical research forward through
investments in compelling
biotech companies.**

Our Venture Portfolio

 <p>ACCENT THERAPEUTICS</p>	 <p>Aldilà THERAPEUTICS</p>	 <p>allo Vir</p>
 <p>anagin</p>	 <p>ARCUS BIOSCIENCES</p>	 <p>ATARA BIO</p>
 <p>ATRECA</p>	 <p>aTyr Pharma Brave Science, Meaningful Medicines</p>	 <p>Avidity NanoMedicines</p>
 <p>clementia</p>	 <p>CODIAK</p>	 <p>COLLEGIUM Pharmaceutical</p>

GENALI™
THERAPEUTICS

DEWPOINT

editas
MEDICINE

elevatebio

FLEXPharma

gossamerbio

Intelia
THERAPEUTICS

KEZAR LIFE SCIENCES


KindredBio
BEST MEDICINES FOR OUR BEST FRIENDS


K U R A
ONCOLOGY


magenta
THERAPEUTICS


METACRINE

MORPHIC
THERAPEUTIC 


nabrive
THERAPEUTICS

 naurex^{INC}
A NEUROPHARMACEUTICAL COMPANY


NEUROGENE

Omniox

 ORIC
Pharmaceuticals

 pellepharm
a bridgebio company

Peloton
Therapeutics 

PREVAIL 
THERAPEUTICS
MOVING TO CURE

 RELAY
THERAPEUTICS

 Rubius Therapeutics

 SAGE
THERAPEUTICS



SCHOLAR ROCK

Syndax 

UNITY
BIOTECHNOLOGY

Z  | ZappRx

Email

info@ecor1cap.com

Phone

415-754-3517

Address

EcoR1 Capital, LLC

409 Illinois Street

San Francisco, CA 94158

COPYRIGHT EcoR1 CAPITAL 2014. ALL RIGHT RESERVED. | [PRIVACY POLICY](#) | [TERMS OF USE](#)